Viva Biotech cancels 11.01 million shares in July, issued share capital falls to 2.09 billion

Bulletin Express08-04

Viva Biotech Holdings (Viva Biotech) filed its Monthly Return for the period ended 31 July 2026, detailing the following key capital movements:

• Issued share count trimmed by 11.01 million shares, to 2.09 billion, after cancellation of stock repurchased on 12 June 2025 and 26 June 2026 at an average price of HKD 1.137593 per share.

• No change in authorised share capital: 4.00 billion ordinary shares with a par value of USD 0.000025, equal to USD 100,000.

• Public-float requirement remains satisfied, with at least 25% of issued shares held by the public.

• Share-based incentives: – Pre-IPO scheme: 2.22 million options outstanding, unchanged during the month. – Post-IPO scheme: options outstanding fell from 13.70 million to 8.32 million after 5.38 million options lapsed; no new grants or exercises. – Aggregate options that could result in future share issuance total 10.54 million, with an additional headroom of 129.73 million shares available for grant under the Post-IPO scheme.

• No warrants, convertible securities, treasury-share transfers, or Hong Kong Depositary Receipts were reported for the month.

The report was submitted on 4 August 2026 and signed by Executive Director Mao Chen Cheney.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1128204785?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-04 15:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128204785","market":"us","top_or_hot":-1,"title":"Viva Biotech cancels 11.01 million shares in July, issued share capital falls to 2.09 billion","media":"Bulletin Express","content":"<p>Viva Biotech Holdings (Viva Biotech) filed its Monthly Return for the period ended 31 July 2026, detailing the following key capital movements:</p>\n<p>• Issued share count trimmed by 11.01 million shares, to 2.09 billion, after cancellation of stock repurchased on 12 June 2025 and 26 June 2026 at an average price of HKD 1.137593 per share.</p>\n<p>• No change in authorised share capital: 4.00 billion ordinary shares with a par value of USD 0.000025, equal to USD 100,000.</p>\n<p>• Public-float requirement remains satisfied, with at least 25% of issued shares held by the public.</p>\n<p>• Share-based incentives:  \n  – Pre-IPO scheme: 2.22 million options outstanding, unchanged during the month.  \n  – Post-IPO scheme: options outstanding fell from 13.70 million to 8.32 million after 5.38 million options lapsed; no new grants or exercises.  \n  – Aggregate options that could result in future share issuance total 10.54 million, with an additional headroom of 129.73 million shares available for grant under the Post-IPO scheme.</p>\n<p>• No warrants, convertible securities, treasury-share transfers, or Hong Kong Depositary Receipts were reported for the month.</p>\n<p>The report was submitted on 4 August 2026 and signed by Executive Director Mao Chen Cheney.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viva Biotech cancels 11.01 million shares in July, issued share capital falls to 2.09 billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViva Biotech cancels 11.01 million shares in July, issued share capital falls to 2.09 billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-04 15:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Viva Biotech Holdings (Viva Biotech) filed its Monthly Return for the period ended 31 July 2026, detailing the following key capital movements:</p>\n<p>• Issued share count trimmed by 11.01 million shares, to 2.09 billion, after cancellation of stock repurchased on 12 June 2025 and 26 June 2026 at an average price of HKD 1.137593 per share.</p>\n<p>• No change in authorised share capital: 4.00 billion ordinary shares with a par value of USD 0.000025, equal to USD 100,000.</p>\n<p>• Public-float requirement remains satisfied, with at least 25% of issued shares held by the public.</p>\n<p>• Share-based incentives:  \n  – Pre-IPO scheme: 2.22 million options outstanding, unchanged during the month.  \n  – Post-IPO scheme: options outstanding fell from 13.70 million to 8.32 million after 5.38 million options lapsed; no new grants or exercises.  \n  – Aggregate options that could result in future share issuance total 10.54 million, with an additional headroom of 129.73 million shares available for grant under the Post-IPO scheme.</p>\n<p>• No warrants, convertible securities, treasury-share transfers, or Hong Kong Depositary Receipts were reported for the month.</p>\n<p>The report was submitted on 4 August 2026 and signed by Executive Director Mao Chen Cheney.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01873","symbol_name":"维亚生物","start_time":0,"source_url":"","article_id":"1128204785","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128204785","pubTimestamp":1785828367,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Viva Biotech Holdings (Viva Biotech) filed its Monthly Return for the period ended 31 July 2026, detailing the following key capital movements: • Issued share count trimmed by 11.01 million shares,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01873":"维亚生物"},"translate_title":"Viva Biotech 7月注销1101万股，已发行股本降至20.9亿","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01873":1},"content_text":"Viva Biotech Holdings (Viva Biotech) filed its Monthly Return for the period ended 31 July 2026, detailing the following key capital movements:\n• Issued share count trimmed by 11.01 million shares, to 2.09 billion, after cancellation of stock repurchased on 12 June 2025 and 26 June 2026 at an average price of HKD 1.137593 per share.\n• No change in authorised share capital: 4.00 billion ordinary shares with a par value of USD 0.000025, equal to USD 100,000.\n• Public-float requirement remains satisfied, with at least 25% of issued shares held by the public.\n• Share-based incentives:  \n  – Pre-IPO scheme: 2.22 million options outstanding, unchanged during the month.  \n  – Post-IPO scheme: options outstanding fell from 13.70 million to 8.32 million after 5.38 million options lapsed; no new grants or exercises.  \n  – Aggregate options that could result in future share issuance total 10.54 million, with an additional headroom of 129.73 million shares available for grant under the Post-IPO scheme.\n• No warrants, convertible securities, treasury-share transfers, or Hong Kong Depositary Receipts were reported for the month.\nThe report was submitted on 4 August 2026 and signed by Executive Director Mao Chen Cheney.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1128204785","isCrawlerRequest":true}